Sustainability | December 12, 2025
Dr. Reddy's Laboratories announces SBTi targets
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The company had achieved the highest "A" rating in Climate Change
The product will be marketed by Dr. Reddy's Laboratories Inc.
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The new site marks the company’s first operation in the region
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Subscribe To Our Newsletter & Stay Updated
